
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1626891/publications.pdf Version: 2024-02-01



AUDREY P ODOM JOHN

#	Article	IF	CITATIONS
1	The Plasmodium falciparum ABC transporter ABCI3 confers parasite strain-dependent pleiotropic antimalarial drug resistance. Cell Chemical Biology, 2022, 29, 824-839.e6.	5.2	14
2	Enzymatic and structural characterization of HAD5, an essential phosphomannomutase of malaria-causing parasites. Journal of Biological Chemistry, 2022, 298, 101550.	3.4	3
3	Cutaneous Findings in SARS-CoV-2-Associated Multisystem Inflammatory Disease in Children. Open Forum Infectious Diseases, 2021, 8, ofab074.	0.9	10
4	Concordance of Preprocedure Testing With Time-of-Surgery Testing for SARS-CoV-2 in Children. Pediatrics, 2021, 147, .	2.1	3
5	Concordance of Upper and Lower Respiratory Tract Samples for SARS-CoV-2 in Pediatric Patients: Research Letter. Anesthesiology, 2021, 134, 970-972.	2.5	1
6	Discrimination of SARS-CoV-2 infected patient samples by detection dogs: A proof of concept study. PLoS ONE, 2021, 16, e0250158.	2.5	44
7	Nonâ€eanonical metabolic pathways in the malaria parasite detected by isotopeâ€tracing metabolomics. Molecular Systems Biology, 2021, 17, e10023.	7.2	12
8	Protein Prenylation and Hsp40 in Thermotolerance of Plasmodium falciparum Malaria Parasites. MBio, 2021, 12, e0076021.	4.1	15
9	#23: Investigation of Phosphomannomutase as an Antimalarial Drug Target. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S10-S10.	1.3	0
10	Structure-guided microbial targeting of antistaphylococcal prodrugs. ELife, 2021, 10, .	6.0	7
11	Reproducible Breath Metabolite Changes in Children with SARS-CoV-2 Infection. ACS Infectious Diseases, 2021, 7, 2596-2603.	3.8	49
12	Targeting Host Glycolysis as a Strategy for Antimalarial Development. Frontiers in Cellular and Infection Microbiology, 2021, 11, 730413.	3.9	6
13	Breath Metabolites to Diagnose Infection. Clinical Chemistry, 2021, 68, 43-51.	3.2	12
14	DNA binding to TLR9 expressed by red blood cells promotes innate immune activation and anemia. Science Translational Medicine, 2021, 13, eabj1008.	12.4	90
15	Evolution of SARS-CoV-2 Seroprevalence Among Employees of a United States Academic Children's Hospital During the COVID-19 Pandemic. Infection Control and Hospital Epidemiology, 2021, , 1-24.	1.8	2
16	Editorial overview: Paths of least resistance: surveillance, discovery, and innovation to address the other (antimicrobial resistance) pandemic. Current Opinion in Microbiology, 2020, 57, iii-v.	5.1	0
17	Antimicrobial Prodrug Activation by the Staphylococcal Glyoxalase GloB. ACS Infectious Diseases, 2020, 6, 3064-3075.	3.8	9
18	Convalescent plasma for pediatric patients with SARSâ€CoVâ€2â€associated acute respiratory distress syndrome. Pediatric Blood and Cancer. 2020. 67. e28693.	1.5	37

#	Article	IF	CITATIONS
19	The Key Glycolytic Enzyme Phosphofructokinase Is Involved in Resistance to Antiplasmodial Glycosides. MBio, 2020, 11, .	4.1	5
20	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. Blood Advances, 2020, 4, 6051-6063.	5.2	105
21	Distinguishing Multisystem Inflammatory Syndrome in Children From Kawasaki Disease and Benign Inflammatory Illnesses in the SARS-CoV-2 Pandemic. Pediatric Emergency Care, 2020, 36, 554-558.	0.9	20
22	The <i>Plasmodium falciparum</i> Artemisinin Susceptibility-Associated AP-2 Adaptin μ Subunit is Clathrin Independent and Essential for Schizont Maturation. MBio, 2020, 11, .	4.1	27
23	Multisystem Inflammatory Syndrome in Children During the Coronavirus 2019 Pandemic: A Case Series. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 393-398.	1.3	317
24	Potent, specific MEPicides for treatment of zoonotic staphylococci. PLoS Pathogens, 2020, 16, e1007806.	4.7	12
25	The Epidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Healthcare Network in the United States. Journal of the Pediatric Infectious Diseases Society, 2020, 9, 523-529.	1.3	59
26	Insights into the intracellular localization, protein associations and artemisinin resistance properties of Plasmodium falciparumÂK13. PLoS Pathogens, 2020, 16, e1008482.	4.7	60
27	The Malaria Metabolite HMBPP Does Not Trigger Erythrocyte Terpene Release. ACS Infectious Diseases, 2020, 6, 2567-2572.	3.8	3
28	Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS–CoV-2. Journal of Clinical Investigation, 2020, 130, 5967-5975.	8.2	319
29	Volatile biomarkers of malaria infection. , 2020, , 349-362.		Ο
30	Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation. Blood, 2020, 136, 28-29.	1.4	0
31	Pediatric tropical medicine: The neglected diseases of children. PLoS Neglected Tropical Diseases, 2019, 13, e0007008.	3.0	4
32	Comparison of breath sampling methods: a post hoc analysis from observational cohort studies. Analyst, The, 2019, 144, 2026-2033.	3.5	6
33	Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering. PLoS ONE, 2019, 14, e0216457.	2.5	19
34	Haloacid Dehalogenase Proteins: Novel Mediators of Metabolic Plasticity in <i>Plasmodium falciparum</i> . Microbiology Insights, 2019, 12, 117863611984843.	2.0	6
35	The Longest Mile: Moving Malaria from Clinical Care to Elimination of Transmission. Clinical Chemistry, 2019, 65, 946-948.	3.2	0
36	Breath Collection from Children for Disease Biomarker Discovery. Journal of Visualized Experiments, 2019, , .	0.3	5

#	Article	IF	CITATIONS
37	Breathprinting Reveals Malaria-Associated Biomarkers and Mosquito Attractants. Journal of Infectious Diseases, 2018, 217, 1553-1560.	4.0	49
38	Malaria in Children. Infectious Disease Clinics of North America, 2018, 32, 189-200.	5.1	14
39	Tackling resistance: emerging antimalarials and new parasite targets in the era of elimination. F1000Research, 2018, 7, 1170.	1.6	18
40	Suppression of Drug Resistance Reveals a Genetic Mechanism of Metabolic Plasticity in Malaria Parasites. MBio, 2018, 9, .	4.1	15
41	MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria. Journal of Medicinal Chemistry, 2018, 61, 8847-8858.	6.4	26
42	Natural History of <i>Plasmodium odocoilei</i> Malaria Infection in Farmed White-Tailed Deer. MSphere, 2018, 3, .	2.9	9
43	Successful treatment of fulminant neonatal enteroviral myocarditis in monochorionic diamniotic twins with cardiopulmonary support, intravenous immunoglobulin and pocapavir. BMJ Case Reports, 2018, 2018, bcr-2017-224133.	0.5	15
44	Inositol phosphate multikinase dependent transcriptional control. Advances in Biological Regulation, 2017, 64, 9-19.	2.3	23
45	Infectious complications of pediatric cochlear implants are highly influenced by otitis media. International Journal of Pediatric Otorhinolaryngology, 2017, 97, 76-82.	1.0	22
46	MEPicides: potent antimalarial prodrugs targeting isoprenoid biosynthesis. Scientific Reports, 2017, 7, 8400.	3.3	26
47	Global proteomic analysis of prenylated proteins in Plasmodium falciparum using an alkyne-modified isoprenoid analogue. Scientific Reports, 2016, 6, 38615.	3.3	63
48	Structure–Activity Relationships of the MEPicides: N-Acyl and O-Linked Analogs of FR900098 as Inhibitors of Dxr from Mycobacterium tuberculosis and Yersinia pestis. ACS Infectious Diseases, 2016, 2, 923-935.	3.8	27
49	Whole-Genome Sequencing to Evaluate the Resistance Landscape Following Antimalarial Treatment Failure With Fosmidomycin-Clindamycin. Journal of Infectious Diseases, 2016, 214, 1085-1091.	4.0	28
50	A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters. Antimicrobial Agents and Chemotherapy, 2016, 60, 7407-7414.	3.2	16
51	Molecular Mechanism of Action of Antimalarial Benzoisothiazolones: Species-Selective Inhibitors of the Plasmodium spp. MEP Pathway enzyme, IspD. Scientific Reports, 2016, 6, 36777.	3.3	13
52	Muddled mechanisms: recent progress towards antimalarial target identification. F1000Research, 2016, 5, 2514.	1.6	6
53	Cap-domain closure enables diverse substrate recognition by the C2-type haloacid dehalogenase-like sugar phosphatase <i>Plasmodium falciparum</i> HAD1. Acta Crystallographica Section D: Biological Crystallography, 2015, 71, 1824-1834.	2.5	14
54	Resistance to the Antimicrobial Agent Fosmidomycin and an FR900098 Prodrug through Mutations in the Deoxyxylulose Phosphate Reductoisomerase Gene (<i>dxr</i>). Antimicrobial Agents and Chemotherapy, 2015, 59, 5511-5519.	3.2	36

#	Article	IF	CITATIONS
55	<i>Plasmodium</i> lspD (2-C-Methyl- <scp>d</scp> -erythritol 4-Phosphate Cytidyltransferase), an Essential and Druggable Antimalarial Target. ACS Infectious Diseases, 2015, 1, 157-167.	3.8	42
56	Malaria Parasites Produce Volatile Mosquito Attractants. MBio, 2015, 6, .	4.1	61
57	Sweet Talk: Regulating Glucose Metabolism in Toxoplasma. Cell Host and Microbe, 2015, 18, 142-143.	11.0	2
58	The Glucose Transporter PfHT1 Is an Antimalarial Target of the HIV Protease Inhibitor Lopinavir. Antimicrobial Agents and Chemotherapy, 2015, 59, 6203-6209.	3.2	26
59	Determinants of Anemia and Hemoglobin Concentration in Haitian School-Aged Children. American Journal of Tropical Medicine and Hygiene, 2015, 93, 1092-1098.	1.4	26
60	Isoprenoid Metabolism in Apicomplexan Parasites. Current Clinical Microbiology Reports, 2014, 1, 37-50.	3.4	63
61	Isoprenoid Biosynthesis in Plasmodium falciparum. Eukaryotic Cell, 2014, 13, 1348-1359.	3.4	53
62	The Triphenylethylenes, a Novel Class of Antifungals. MBio, 2014, 5, e01126-14.	4.1	12
63	A sugar phosphatase regulates the methylerythritol phosphate (MEP) pathway in malaria parasites. Nature Communications, 2014, 5, 4467.	12.8	69
64	Isoprenoid Biosynthesis Inhibition Disrupts Rab5 Localization and Food Vacuolar Integrity in Plasmodium falciparum. Eukaryotic Cell, 2013, 12, 215-223.	3.4	62
65	Structural Studies and Protein Engineering of Inositol Phosphate Multikinase. Journal of Biological Chemistry, 2012, 287, 35360-35369.	3.4	28
66	The MEP pathway and the development of inhibitors as potential anti-infective agents. MedChemComm, 2012, 3, 418.	3.4	41
67	A Second Target of the Antimalarial and Antibacterial Agent Fosmidomycin Revealed by Cellular Metabolic Profiling. Biochemistry, 2011, 50, 3570-3577.	2.5	142
68	Five Questions about Non-Mevalonate Isoprenoid Biosynthesis. PLoS Pathogens, 2011, 7, e1002323.	4.7	46
69	Functional genetic analysis of the Plasmodium falciparum deoxyxylulose 5-phosphate reductoisomerase gene. Molecular and Biochemical Parasitology, 2010, 170, 108-111.	1.1	60
70	100 Best Books for Children. JAMA Pediatrics, 2004, 158, 1189.	3.0	0
71	Molecular and Biochemical Characterization of Two Plant Inositol Polyphosphate 6-/3-/5-Kinases. Journal of Biological Chemistry, 2002, 277, 42711-42718.	3.4	120
72	Characterization of the MFα pheromone of the human fungal pathogen Cryptococcus neoformans. Molecular Microbiology, 2002, 38, 1017-1026.	2.5	66

#	Article	IF	CITATIONS
73	An expanded view of inositol signaling. Advances in Enzyme Regulation, 2001, 41, 57-71.	2.6	85
74	A Role for Nuclear Inositol 1,4,5-Trisphosphate Kinase in Transcriptional Control. Science, 2000, 287, 2026-2029.	12.6	377
75	A Phospholipase C-Dependent Inositol Polyphosphate Kinase Pathway Required for Efficient Messenger RNA Export. Science, 1999, 285, 96-100.	12.6	508
76	Nickel Inhibits Binding of α2-Macroglobulin-Methylamine to the Low-Density Lipoprotein Receptor-Related Protein/α2-Macroglobulin Receptor but Not the α2-Macroglobulin Signaling Receptorâ€. Biochemistry, 1997, 36, 12395-12399.	2.5	23
77	The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrobial Agents and Chemotherapy, 1997, 41, 156-161.	3.2	146
78	Calcineurin is required for virulence of Cryptococcus neoformans. EMBO Journal, 1997, 16, 2576-2589.	7.8	458
79	The Effect of Acrylamide and Other Sulfhydryl Alkylators on the Ability of Dynein and Kinesin to Translocate Microtubules in Vitro. Toxicology and Applied Pharmacology, 1995, 133, 73-81.	2.8	25